Analysts expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce sales of $60,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 100%. The company is expected to announce its next earnings results on Friday, November 3rd.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year sales of $60,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $500,000.00. For the next fiscal year, analysts expect that the company will post sales of $240,000.00 per share, with estimates ranging from $100,000.00 to $500,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million.

A number of analysts recently issued reports on the company. Vetr downgraded Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 price target for the company. in a research report on Wednesday, September 6th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Tuesday, August 15th. Finally, Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $9.79.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded up 1.13% on Friday, hitting $6.27. 400,990 shares of the company traded hands. The stock’s market capitalization is $523.45 million. The firm’s 50 day moving average price is $6.22 and its 200-day moving average price is $6.72. Aurinia Pharmaceuticals has a 1-year low of $2.02 and a 1-year high of $10.54.

TRADEMARK VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $60,000.00” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/aurinia-pharmaceuticals-inc-auph-expected-to-post-quarterly-sales-of-60000-00/1601614.html.

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in shares of Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $155,000. Cutler Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Investment Centers of America Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Two Sigma Securities LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $240,000. Institutional investors and hedge funds own 27.76% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.